Search Results for: PRKACA

219 interactions involving PRKACA - protein kinase cAMP-activated catalytic subunit alpha found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PDC phosducin
PDE3A phosphodiesterase 3A
  • G alpha (s) signalling events
  • Caffeine
  • Milrinone
  • Anagrelide
  • Theophylline
  • Levosimendan
  • Cilostazol
  • Aminophylline
  • Oxtriphylline
  • Amrinone
  • Enoximone
  • Ibudilast
  • Tofisopam
  • Trapidil
PDE3B phosphodiesterase 3B
  • PDE3B signalling
  • PDE3B signalling
  • G alpha (s) signalling events
  • Caffeine
  • Caffeine
  • Amrinone
  • 6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
  • Hg9a-9, Nonanoyl-N-Hydroxyethylglucamide
  • 3-isobutyl-1-methyl-7H-xanthine
  • Trapidil
PDE4B phosphodiesterase 4B
  • DARPP-32 events
  • Adenosine phosphate
  • Caffeine
  • Caffeine
  • Theophylline
  • Dyphylline
  • Enprofylline
  • Iloprost
  • Papaverine
  • Theobromine
  • Amrinone
  • Daxalipram
  • Roflumilast
  • Piclamilast
  • Rolipram
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Filaminast
  • 8-Bromo-Adenosine-5'-Monophosphate
  • (S)-Rolipram
  • 1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Cilomilast
  • (R)-Rolipram
  • S,S-(2-Hydroxyethyl)Thiocysteine
  • Crisaborole
  • Ibudilast
  • 1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
  • Trapidil
PDE4D phosphodiesterase 4D
  • DARPP-32 events
  • G alpha (s) signalling events
  • Adenosine phosphate
  • Caffeine
  • Caffeine
  • Dyphylline
  • Iloprost
  • Amrinone
  • Roflumilast
  • Piclamilast
  • Rolipram
  • 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
  • Zardaverine
  • 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • (S)-Rolipram
  • Cilomilast
  • (R)-Rolipram
  • 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
  • Crisaborole
  • Ibudilast
  • Tetomilast
  • Exisulind
  • (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
  • 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
  • 3-isobutyl-1-methyl-7H-xanthine
  • 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
  • Trapidil
PDPK1 3-phosphoinositide dependent protein kinase 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Activation of AKT2
  • Downstream TCR signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated NF-kB activation
  • Integrin signaling
  • CD28 dependent PI3K/Akt signaling
  • G beta:gamma signalling through PI3Kgamma
  • RSK activation
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • CLEC7A (Dectin-1) signaling
  • RHO GTPases activate PKNs
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Estrogen-stimulated signaling through PRKCZ
  • Estrogen-stimulated signaling through PRKCZ
  • Celecoxib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • 7-Hydroxystaurosporine
  • Bisindolylmaleimide VIII
  • Staurosporine
  • Bisindolylmaleimide I
  • Dexfosfoserine
  • 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
  • 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
  • 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
  • 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
  • 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  • 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
  • Fostamatinib
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1
  • PKA-mediated phosphorylation of key metabolic factors
  • PP2A-mediated dephosphorylation of key metabolic factors
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • D-Gluco-2,5-Anhydro-1-Deoxy-1-Phosphonohexitol-6-Phosphate
  • sn-glycerol 3-phosphate
  • Adenosine 5'-[gamma-thio]triphosphate
  • Guanosine-5'-Triphosphate
  • Fructose-6-phosphate
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
PHKA1 phosphorylase kinase regulatory subunit alpha 1
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
PHOX2A paired like homeobox 2A
  • Congenital fibrosis of the extraocular muscles (CFEOM)
PKIA cAMP-dependent protein kinase inhibitor alpha
  • 3,5-Diiodotyrosine
  • Hydroxyfasudil
  • (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
  • (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
  • (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
  • (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
  • N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
  • (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
  • (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • H-89
  • 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
  • N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
  • 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • 3-pyridin-4-yl-1H-indazole
  • 5-benzyl-1,3-thiazol-2-amine
  • 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
  • Fasudil
  • Myristic acid
  • A-674563
  • 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
  • Y-27632
PKIB cAMP-dependent protein kinase inhibitor beta
PLIN1 perilipin 1
  • Triglyceride catabolism
  • Transcriptional regulation of white adipocyte differentiation
  • NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose
PLN phospholamban
  • Ion homeostasis
  • Ion transport by P-type ATPases
POU2F1 POU class 2 homeobox 1
  • Interleukin-4 and Interleukin-13 signaling
  • RNA polymerase II transcribes snRNA genes
  • RNA polymerase II transcribes snRNA genes
  • RNA Polymerase III Abortive And Retractive Initiation
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • RNA Polymerase III Transcription Initiation From Type 3 Promoter
  • Estrogen-dependent gene expression
PPP1R10 protein phosphatase 1 regulatory subunit 10
PPP1R17 protein phosphatase 1 regulatory subunit 17
PPP1R1B protein phosphatase 1 regulatory inhibitor subunit 1B
  • DARPP-32 events
  • DARPP-32 events
PPP1R8 protein phosphatase 1 regulatory subunit 8
PPP1R9B protein phosphatase 1 regulatory subunit 9B

Page 8 out of 11 pages